News

Telix Pharmaceuticals and partners receive $500K research grant from Government funded Innovative Manufacturing CRC

Melbourne (Australia) – 16 Mar 2020. Telix and partners receive $500K research grant from Government-funded Innovative Manufacturing CRC to advance manufacturing of novel cancer drugs

Telix Pharmaceuticals Limited is pleased to announce it is a co-recipient of a $500,000 research grant from the Government-funded Innovative Manufacturing Cooperative Research Centre (IMCRC) to fund R&D aimed at advancing Australian manufacturing capabilities for molecularly-targeted radiation (MTR) drugs for prostate, kidney and neuroendocrine cancers.

The research grant has been awarded to a group of Melbourne, Victoria-based organisations brought together by the IMCRC, comprising Telix, Cyclotek, GenesisCare, iPHASE Technologies and the School of Chemistry, Bio21 Institute, University of Melbourne.

To read the full media release please click here.

More Articles

ASX Announcements

Telix Pharmaceuticals Enters Commercial Distribution Agreement for Prostate Cancer Diagnostic

Indianapolis IN and Columbus OH (U.S.A) – 8 April 2020. Telix Pharmaceuticals (U.S.) Inc. is pleased to announce it has...

News

Telix Pharmaceuticals and partners receive $500K research grant from Government funded Innovative Manufacturing CRC

Melbourne (Australia) – 16 Mar 2020. Telix and partners receive $500K research grant from Government-funded Innovative Manufacturing CRC to advance...

News

Business Update : COVID-19

Melbourne (Australia) – 13 Mar 2020. Telix provides an update on the Company’s risk management assessment of the novel coronavirus...

News

Leader in prostate cancer imaging Prof. Frederik L. Giesel joins Scientific Advisory Board

Melbourne (Australia) – 9 March 2020. Telix Pharmaceuticals Limited announces that Professor Dr. Frederik L. Giesel, MD, MBA has joined...

News

Positive FDA Feedback on NDA Submission Process for TLX591-CDx (kit for the preparation of 68Ga-PSMA-11)

Melbourne (Australia) – 25 Feb 2020. Telix Pharmaceuticals announces that it has received positive feedback from the FDA regarding its...

News

Telix Pharmaceuticals Releases Annual Report Year Ending 2019

Melbourne (Australia) - 24 Feb 2020. Telix Pharmaceuticals Limited is pleased to provide its Annual Report for the year ending...

News

European Leadership Changes and Appointment of VP Sales and Marketing, EMEA

Melbourne (Australia) – 21st February 2020. Telix Pharmaceuticals Limited announces that Ms Odile Jaume will be stepping down from her...

ASX Release

Telix completes acquisition of European radiopharmaceutical production facility

Melbourne (Australia) – 3 April 2020. Telix is pleased to announce it has now completed the acquisition of a licensed...